1. Home
  2. ADCT vs MVBF Comparison

ADCT vs MVBF Comparison

Compare ADCT & MVBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADCT
  • MVBF
  • Stock Information
  • Founded
  • ADCT 2011
  • MVBF 1997
  • Country
  • ADCT Switzerland
  • MVBF United States
  • Employees
  • ADCT N/A
  • MVBF N/A
  • Industry
  • ADCT Biotechnology: Pharmaceutical Preparations
  • MVBF Major Banks
  • Sector
  • ADCT Health Care
  • MVBF Finance
  • Exchange
  • ADCT Nasdaq
  • MVBF Nasdaq
  • Market Cap
  • ADCT 241.0M
  • MVBF 278.3M
  • IPO Year
  • ADCT 2020
  • MVBF N/A
  • Fundamental
  • Price
  • ADCT $3.17
  • MVBF $23.22
  • Analyst Decision
  • ADCT Strong Buy
  • MVBF Buy
  • Analyst Count
  • ADCT 6
  • MVBF 4
  • Target Price
  • ADCT $7.80
  • MVBF $24.75
  • AVG Volume (30 Days)
  • ADCT 913.9K
  • MVBF 45.9K
  • Earning Date
  • ADCT 08-05-2025
  • MVBF 07-28-2025
  • Dividend Yield
  • ADCT N/A
  • MVBF 2.88%
  • EPS Growth
  • ADCT N/A
  • MVBF N/A
  • EPS
  • ADCT N/A
  • MVBF 1.46
  • Revenue
  • ADCT $75,817,000.00
  • MVBF $146,101,000.00
  • Revenue This Year
  • ADCT $11.75
  • MVBF N/A
  • Revenue Next Year
  • ADCT $10.29
  • MVBF $14.22
  • P/E Ratio
  • ADCT N/A
  • MVBF $16.15
  • Revenue Growth
  • ADCT 10.49
  • MVBF N/A
  • 52 Week Low
  • ADCT $1.05
  • MVBF $15.59
  • 52 Week High
  • ADCT $4.13
  • MVBF $25.24
  • Technical
  • Relative Strength Index (RSI)
  • ADCT 59.73
  • MVBF 79.48
  • Support Level
  • ADCT $2.66
  • MVBF $22.85
  • Resistance Level
  • ADCT $3.30
  • MVBF $23.63
  • Average True Range (ATR)
  • ADCT 0.20
  • MVBF 0.50
  • MACD
  • ADCT 0.01
  • MVBF 0.13
  • Stochastic Oscillator
  • ADCT 90.00
  • MVBF 95.93

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About MVBF MVB Financial Corp.

MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.

Share on Social Networks: